Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 25;10(3):29-36.
doi: 10.5527/wjn.v10.i3.29.

Nephrogenic systemic fibrosis: A frivolous entity

Vinant Bhargava  1 , Kulwant Singh  2 , Priti Meena  3 , Rupan Sanyal  4
Affiliations
Review

Nephrogenic systemic fibrosis: A frivolous entity

Vinant Bhargava et al. World J Nephrol. .

Abstract

Gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging are vital in providing enhanced quality images, essential for diagnosis and treatment. Nephrogenic systemic fibrosis (NSF) with GBCAs has been a deterrent for the physician and has led to avoidance of these agents in patients with impaired kidney function. NSF is a progressive debilitating multisystem condition described classically in patients with renal insufficiency exposed to gadolinium contrast media. It is characterized by an induration and hardening of the skin. NSF is described to first involve the extremities and can imperceptibly involve internal organs. Lack of therapeutic interventions to treat NSF makes it more challenging and warrants deep insight into the pathogenesis, risk factors and treatment strategies.

Keywords: Chronic kidney disease; Dialysis; End stage kidney disease; Gadolinium-based contrast agents; Magnetic resonance imaging; Nephrogenic systemic fibrosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: There is no conflict of interest to disclose.

Figures

Figure 1
Figure 1
Postulated pathophysiology of nephrogenic systemic fibrosis. PTH: Parathyroid Hormone; ECM: Extracellular matrix; hPMBC: Human peripheral mononuclear blood cells; MCP-2: Monocyte chemoattractant protein-2; MMP: Metalloproteinases; TIMP: Tissue inhibitor of metalloproteinase.
See this image and copyright information in PMC

References

    1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001. - PubMed
    1. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum. 2006;35:208–210. - PubMed
    1. Waikhom R, Taraphder A. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56:54–58. - PMC - PubMed
    1. Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376–386. - PubMed
    1. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785–790. - PubMed